Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002335652 | SCV002641829 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-12-03 | criteria provided, single submitter | clinical testing | The p.H168L pathogenic mutation (also known as c.503A>T), located in coding exon 4 of the TP53 gene, results from an A to T substitution at nucleotide position 503. The histidine at codon 168 is replaced by leucine, an amino acid with similar properties. This alteration has been reported in an individual with a personal history of leiomyosarcoma diagnosed at age 39 (Ballinger ML et al. JAMA Oncol, 2017 12;3:1735-1736). This variant is in the DNA binding domain of the TP53 protein and is reported to have non-functional transactivation in yeast based assays (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9). Studies conducted in human cell lines indicate this alteration is deficient at growth suppression and has a dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). Another alteration at the same codon, p.H168R (c.503A>G), has been reported in patients meeting Chompret criteria (Ambry internal data; Bakhuizen JJ et al. Fam Cancer, 2019 04;18:273-280). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |